Johnson & Johnson wins FDA approval for ThermoCool SmartTouch dual-energy ablation system

Johnson & Johnson (NYSE:JNJ) announced today that it received FDA approval for its dual-energy ThermoCool SmartTouch SF platform (DE STSF).

The ThermoCool SmartTouch platform combines the ThermoCool SmartTouch SF catheter with the TruPulse generator. Combining the irrigated contact-force-sensing catheter with TruPulse enables the delivery of both radiofrequency (RF) and pulsed field (PF) energy. It all takes place through a single catheter-based solution.

FDA approval comes on the heels of the European launch for ThermoCool SmartTouch SF, announced two weeks ago. Other companies are also looking to make their mark in dual-energy ablation, with Abbott and Medtronic advancing programs.

Sign up for Blog Updates